Search Results

In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.

With total spending on U.S. cancer care projected to rise 34 percent from 2015-2030 to $245 billion, biosimilars can play a role in helping reduce those costs. Learn how Biden’s executive order on promoting competition in the American economy will require the FDA's biosimilars approval framework to be clearer and easier to follow.